Enumeral Biomedical Holdings (f/d/b/a Cerulean Group) and two affiliated Debtors filed for Chapter 11 protection with the U.S. Bankruptcy Court in the District of Massachusetts, case number 18-10280.
The Company, which engages in discovering and developing antibody immunotherapies that help the immune system fight cancer and other diseases, is represented by Daniel C. Cohn of Murtha Cullina. According to documents filed with the Court, the Company intends to sell substantially all of its assets to XOMA US for a price of $1.6 million, pending Court approval and/or higher or otherwise better offers.
Read more bankruptcy news.
The post Enumeral Biomedical Bankruptcy, Sale Announced appeared first on Daily Bankrupt Company Updates | Bankrupt Company News.